Navigation Links
Renal denervation treats resistant hypertension in real world patient populations
Date:8/27/2012

Munich, Germany August 27 2012: Renal denervation successfully treats patients with resistant hypertension in real world patient populations, according to a study presented at ESC Congress 2012. The findings were presented by Dr Darren Mylotte from France.

Transcatheter renal denervation represents a novel therapy for treating patients with treatment resistant hypertension, a condition which greatly increases the risk of myocardial infarction and stroke.

"The Symplicity Hypertension I and II studies have suggested that this procedure significantly lowers blood pressure in these patients with few remaining options in terms of treatment," said Dr Mylotte. "However, patients included in clinical trials are often highly selected, and therefore may not reflect the patient encountered by physicians on a day-to-day basis. As such, the results of these trials may not be applicable to less-selected patient populations."

In light of this potential problem, the investigators sought to evaluate the effect of transcatheter renal denervation in a group of patients with resistant hypertension in their own clinical practice at The Institut Cardiovasculaire de Paris Sud, Paris, France.

They intended to perform transcatheter renal denervation on 35 consecutive patients referred to the service with resistant hypertension. The study used the same definition as the Symplicity trials to define resistant hypertension (1).

Among these patients, 36.5% were female, 36.4% were diabetic, and 15.2% had kidney dysfunction. Baseline office blood pressure (BP) was 181.121.9 /100.816.8 mmHg, despite an average of 4.61.0 medications per patient. Successful bilateral sympathetic denervation was performed in 33 out of 35 patients (1 patient was not treated due to a stenosis of the renal artery; 1 patient had treatment on one side only, as multiple small renal arteries were found on the other side). No procedural complications occurred.

At 6-months follow-up, the average office BP reduction from baseline was 30.321.1/14.615.3 mmHg (P<0.0001). Similarly, ambulatory BP was reduced 23.312.1/10.29.9 mmHg from baseline (P<0.001). There were no adverse events during follow-up (death, myocardial infarction, or stroke), and no deterioration in renal function was observed.

"Transcatheter renal denervation is a safe and efficacious treatment, which results in significant reductions in blood pressure in real world patients with treatment resistant hypertension," said Dr Mylotte. "Although longer-term results are required, renal denervation should be considered for all patients with treatment resistant hypertension, as it is likely to lower their blood pressure and reduce their chances of myocardial infarction and stroke."


'/>"/>

Contact: ESC Press Office
press@escardio.org
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Newborn Screening May Miss Adrenal-Gland Disorder
2. Broken heart syndrome protects the heart from adrenaline overload
3. Renal denervation gives better outcomes than drugs in advanced heart failure
4. Intense light prevents, treats heart attacks
5. Novel radiation therapy safely treats prostate cancer and lowers the risk of recurrence
6. Kinase test may yield big gains for drug-resistant cancers
7. New drug strategy attacks resistant leukemia and lymphoma
8. Einstein awarded $6 million grant to develop new TB vaccine against drug-resistant strains
9. New Medicine Might Fight Drug-Resistant TB, Study Says
10. Antibiotic-Resistant Gonorrhea Spreading: WHO
11. Rare Drug-Resistant Bacteria Spotted in U.S. Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified ... be personalized through a fitness app. The fitness app plans to fix the two major ... only offer a one size fits all type program , They don’t eliminate ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... June 24, 2016 ... announced the addition of the " Global Markets ... This report focuses ... an updated review, including its applications in various applications. ... market, which includes three main industries: pharmaceutical and biotechnology, ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
Breaking Medicine Technology: